Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Amortization of Deferred Charges (2021 - 2023)

GeneDx Holdings (WGS) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $130000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Amortization of Deferred Charges changed 0.0% to $130000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $518000.0, a 14.35% increase, with the full-year FY2022 number at $518000.0, up 684.85% from a year prior.
  • Amortization of Deferred Charges was $130000.0 for Q3 2023 at GeneDx Holdings, up from $129000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $131000.0 in Q4 2022 to a low of $66000.0 in Q4 2021.
  • A 3-year average of $121375.0 and a median of $129000.0 in 2022 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: soared 98.48% in 2022, then changed 0.0% in 2023.
  • GeneDx Holdings' Amortization of Deferred Charges stood at $66000.0 in 2021, then skyrocketed by 98.48% to $131000.0 in 2022, then fell by 0.76% to $130000.0 in 2023.
  • Per Business Quant, the three most recent readings for WGS's Amortization of Deferred Charges are $130000.0 (Q3 2023), $129000.0 (Q2 2023), and $128000.0 (Q1 2023).